disability progression

October 26, 2017October 26, 2017

#MSParis2017 – Tysabri Did Improve Walking and Hand Function in Failed SPMS Trial, Researchers Say

News

While Tysabri (natalizumab) failed to slow worsening disability in people with secondary progressive multiple sclerosis (SPMS) in a Phase 3 trial, researchers now suggest that the ... Read more

October 26, 2017October 27, 2017

#MSParis2017 – Siponimod Leads to Dramatic Drop in MS Lesions, Phase 3 Trial Shows

News

Novartis’ Siponimod led to a dramatic drop in the number of inflammation patches in the brains and spinal cords of secondary progressive multiple sclerosis patients, according to a ... Read more

April 28, 2017April 28, 2017

Siponimod Slows Progression of MS Disability, Phase 3 Clinical Trial Shows

News

Siponimod slows the progression of multiple sclerosis patients’ disability, a Phase 3 clinical trial indicates. The therapy reduced the risk of disability progression in patients with secondary ... Read more

April 28, 2017April 28, 2017

Lemtrada Might Outperform Ocrevus in Preventing MS Relapses, Italian Researchers Say

News

Lemtrada (alemtuzumab) may be more effective in preventing relapses in multiple sclerosis patients than the newly approved Ocrevus (ocrelizumab), according to a study presented April 28 at the ... Read more

September 21, 2016September 21, 2016

#ECTRIMS2016 – Novartis’s Siponimod Appears to Slow SPMS Progression in Phase 3 Study

News

A presentation at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016 Congress gave patients with progressive multiple sclerosis (MS) a reason for optimism, ... Read more

September 21, 2016September 21, 2016

#ECTRIMS2016 – 2 Rounds of Lemtrada Seen to Effectively Treat MS Relapses for Years

News

Lemtrada (alemtuzumab) as a first treatment option for relapsing multiple sclerosis (MS) patients reduced relapse rates and disability progression throughout a study period of six years ... Read more

August 29, 2016October 31, 2016

Gilenya-like Therapy Shows Benefit in Secondary Progressive MS Patients in Phase 3 Trial

News

Patients with secondary progressive multiple sclerosis (SPMS) who were treated with BAF312 (siponimod), a sphingosine-1-phosphate (S1P) inhibitor, in a Phase 3 clinical trial showed a significantly reduced risk for disability ... Read more

June 6, 2016September 14, 2016

#CMSC16 – RRMS Patients on Alemtuzumab (Lemtrada) Show Slowed Disability Progression Over Five Years

News

A study of relapsing-remitting multiple sclerosis (RRMS) patients who had one or more relapses on earlier treatment, showed that alemtuzumab (Lemtrada) improved disability progression over five ... Read more

February 18, 2016February 19, 2016

ACTRIMS Session on MS Progression to Emphasize Continuing Treatment of Advancing Disease

News

The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016 starts today, Feb. 18, in New Orleans, Louisiana, and runs through Saturday, Feb. ... Read more

April 23, 2015April 23, 2015

NYU Langone Researchers Report What Happens When Multiple Sclerosis Patients Abandon Treatment

Multiple Sclerosis News, News

A team led by researchers at the New York University (NYU) Langone Medical Center recently assessed what happens when clinically stable patients with multiple sclerosis (MS) ... Read more

Pin It on Pinterest